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Mutant hepatitis B virus with substitutions within the coding region for HBV surface antigen (HBsAg) has been found naturally in
chronic carriers. It is therefore important to clarify whether the identified substitutions within the HBsAg have impact on the antigenicity and
immunogenicity of HBsAg. A total of nine mutated HBV s-genes with single representative mutations were generated by site-directed
mutagenesis and subcloned into an expression vector. The binding of polyclonal and monoclonal antibodies to these mutant HBsAg
(mtHBsAg) was tested by immunofluorescence (IF) staining of cells transfected with the expression vectors. The amino acid (aa)
substitutions like G145R, F134S, and C147W affected the binding of anti-HBs antibodies to corresponding mtHBsAg to different extents.
The impact of aa substitutions G145R and F134S on the immunogenicity was accessed by genetic immunization of mice with vectors
expressing middle HBsAg with the corresponding mutations. The immunized mice developed antibodies to recombinant HBsAg containing
the HBV preS region and HBsAg-specific cytotoxic T-cell. However, the development of antibody response to wild-type small HBsAg was
significantly impaired by the aa substitutions in HBsAg. Based on this fact, we further investigated whether the mtHBsAg with the aa
substitution G145R is able to induce mutant-specific antibody responses. Strikingly, serum samples from mice immunized with mtHBsAg
with G145R recognized plasma-derived mtHBsAg. Two mouse MAbs specific to mtHBsAg were generated. One MAb recognized mtHBsAg
with G145R but not wild type and other mtHBsAg. We conclude that HBsAg with aa substitutions are immunogenic but may have a changed
fine specificity.
D 2004 Elsevier Inc. All rights reserved.
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Hepatitis B virus (HBV) is an enveloped virus and causes
acute self-limited and chronic infections in human (Hollinger
and Liang, 2001). Chronic HBV infection is one of the major0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: mengji.lu@uni-essen.de (M. Lu).causes for liver diseases, cirrhosis, and hepatocellular
carcinomas. HBV infection can be prevented by vaccination
with recombinant hepatitis B surface antigens (HBsAg)
(Szmuness et al., 1981). HBsAg induces specific anti-HBs
antibodies that are mainly directed to the central region of
HBsAg termed as a-determinant (Bhatanagar et al., 1985;
Brown et al., 1984; Chen et al., 1996; Schirmbeck et al.,
2001; Zheng et al., 2002). However, HBV mutants with
changed surface antigens are able to escape immune control04) 454–464
X. Zheng et al. / Virology 329 (2004) 454–464 455(for reviews, see Carman, 1997; Cooreman et al., 1999;
Gunther et al., 1999). HBVescape mutants were found first in
children immunized with HBsAg (Carman et al., 1996;
Karthigesu et al., 1994). Though they developed anti-HBs
antibodies at the protective level, persistent HBV infection
occurred in some individuals. HBV mutants may emerge and
cause infection in liver transplant patients and infants born to
HBV carrier mothers receiving hyperimmunoglobulin
against HBVas immunoprophylaxis (Carman, 1997; Carman
et al., 1999; Chiou et al., 1997; Ghany et al., 1998; He et al.,
1998; Hsu et al., 1997; Lee et al., 1997; Ni et al., 1995;
Protzer et al., 1998; Sterneck et al., 1997;Waters et al., 1992).
The sequence analysis of HBV isolates from these patients
revealed that the HBsAg carries amino acid (aa) substitutions
within the a-determinant. These aa substitutions reduce the
binding affinity of HBsAg to specific antibodies and
probably enable HBV to escape the neutralization by anti-
HBs antibodies (Chiou et al., 1997; Cooreman et al., 2001;
Grethe et al., 1998; Ireland et al., 2000; Lu and Lorentz, 2003;
Seddigh-Tonekaboni et al., 2000; Waters et al., 1992).
Sequences of natural HBVisolates show a great variability
(Gunther et al., 1999; Norder et al., 1993). HBV isolates
carrying substitutions within the HBsAg a-determinant were
found to occur in chronic HBV-infected patients, such with
anti-HBc antibody as the only marker (Carman et al., 1997;
Grethe et al., 1998; Hou et al., 2001; Kohno et al., 1996;
Oguru et al., 1999; Weinberger et al., 2000; Yamamoto et al.,
1994). The presence of HBV mutants in the general
population imply that they circulate naturally; thus, they
might cause acute and chronic HBV infection, particularly in
some individuals like immune compromised patients despite
of the immunoprophylaxis. However, the influence of these
identified aa substitutions of HBsAg on the antigenicity and
immunogenicity of HBsAg is not obvious. The recent
approach to define the antigenicity of mutant HBsAg
(mtHBsAg) is to use monoclonal anti-HBs antibodies to
detect mutant HBsAg in immunofluorescence (IF) staining,
as demonstrated in several studies (Chiou et al., 1997;
Cooreman et al., 2001; Torresi et al., 2002). It has been shown
that the binding of monoclonal antibodies to HBsAg may be
affected by aa substitutions within the a-determinant. Further,
we and other groups explored the genetic immunization as a
tool to study the immunogenicity of wild type HBsAg
(wtHBsAg) and mtHBsAg (Lu and Lorentz, 2003; Schirm-
beck et al., 2003; Wu et al., 1999; Zheng et al., 2002). The
results of these studies indicate that the a-determinant is the
only immunogenic region on the HBsAg polypeptides. The
mtHBsAg have a reduced ability to induce anti-HBs anti-
bodies while the induction of HBsAg-specific cytotoxic T
lymphocytes was not impaired (Lu and Lorentz, 2003). Thus,
suitable methods are available to judge the antigenicity and
immunogenicity of mtHBsAg.
Two important issues about mtHBsAg are not studied in
detail up to date. First, aa substitutions within the HBsAg
occur usually at many positions (Weinberger et al., 2000).
The significance of single aa substitutions on the antigenictyand immunogenicity is often not clear. Second, mtHBsAg are
immunogenic since they are able to induce normal CTL
responses (Lu and Lorentz, 2003). Though they often failed
to induce a detectable anti-HBs antibody response, they may
possibly prime antibody response with a changed specificity.
In the present study, we focused on these two topics. A total of
nine single mutations found in patients with anti-HBc
antibody as the only marker for HBV infection was selected
and introduced into a HBsAg subtype adw2 sequence by site-
directed mutagenesis. The influence of these specific aa
substitutions on the antigenicity of HBsAg was examined by
transient expression and IF staining with polyclonal and
monoclonal antibodies (MAb) to HBsAg and with purified
immunoglobulins (IgGs) from human anti-HBs positive sera.
Particular attention was paid to mtHBsAg with aa substitu-
tions G145R and Y134S. The ability of these two different
mtHBsAgs to induce specific antibody and CTL responses
was assessed by genetic immunization in mice. To differ-
entiate the specificity of antibodies induced by genetic
immunization, ELISAs using different antigens HBsAg,
middle HBsAg (MHBsAg) with the preS domain, and
mtHBsAg with aa substitution G145R were performed with
sera of immunized mice. The induction of CTLs to the H-2Ld
restricted epitope on HBsAg aa 29–38 in BALB/cJ (H-2d)
mice were assessed by in vitro expansion and staining of
specific CTLs. Finally, MAbs specific to mtHBsAg with
G145R were generated by a combination of plasmid and
protein immunization for further analysis of the fine
specificity of the antibody response to mtHBsAg.Results
Reduced binding of antibodies to HBsAg a-determinant to
HBsAg with single mutations
Previously, a series of mutations within the a-determinant
of HBsAg were identified by sequencing of HBV isolates
from patients with anti-HBc as only marker for HBV
infection (Weinberger et al., 2000). Some of these mutations
had been described early (Gunther et al., 1999). In addition,
novel mutations within or adjacent to the a-determinant like
T125M, K141Q, and P153A were identified. These muta-
tions represent nonconservative aa substitutions and therefore
may have influence on the conformation of HBsAg a-
determinant and the binding of HBsAg-specific antibodies.
To investigate the influence of these mutations on the
antigenicity and immunogenicity of HBsAg, PCR-based
mutagenesis was performed to introduce nine selected single
mutations into the a-determinant of an adw2 WT sequence
(pHBV991-12-1, GenBank accession number X51970). The
mutated sequences were recloned into pcDNA3 and placed
under the control of a cytomegalovirus immediate–early
promoter (Fig. 1).
To examine whether the mutations within the HBsAg
lead to the alteration of binding of HBsAg to specific anti-
X. Zheng et al. / Virology 329 (2004) 454–464456HBsAg antibodies, various cell lines including hepG2 cells
were transiently transfected with vectors expressing
mtHBsAg and wtHBsAg and stained with a polyclonal
anti-HBs and different monoclonal anti-HBs antibodies. In
addition, IgGs purified from human anti-HBs positive sera
were tested for their reactivity to mtHBsAg by IF staining.
The representative results of IF staining with anti-HBs
antibodies are summarized in Fig. 2.
WtHBsAg was clearly stained with polyclonal and a
monoclonal anti-HBs antibody (Dako clone 3E7) (Fig. 2).
Three of nine mtHBsAg T125M, P127T, and P153A were
stained with both polyclonal and monoclonal antibodies like
wtHBsAg. Obviously, many aa substitutions on the HBsAg
do not affect the binding of specific anti-HBs antibodies.
The staining of mtHBsAg F134S and S154P with poly-
clonal anti-HBs antibodies was comparable with the staining
of the wtHBsAg, while staining with monoclonal antibodies
resulted into a reduced intensity (Fig. 2). Thus, these
mutations led to a reduced binding to antibodies with a
defined specificity. The mutation at the aa position 147 of
HBsAg led to a loss of a cystein residue that is involved in
the intermolecular disulfide bond formation (Mangold et al.,
1995). The mtHBsAg C147W was stained by polyclonal
anti-HBs but failed to be detected in a commercial HBsAg
ELISA (Enzygnost HBsAg 5.0, Dade Behring). The
monoclonal anti-HBs antibody failed to recognize HBsAg
C147W. mtHBsAg K141Q and S154V showed a reduced
staining with both polyclonal antibodies and MAb. The
mtHBsAg G145R were not recognized by IF staining with
both polyclonal and monoclonal antibodies. The aa residue
at the position 145 of HBsAg has been identified as a critical
residue for antibody response (Carman et al., 1990).
However, the mtHBsAg could be stained with a high-affineFig. 1. Top: Map of antigenic regions within the HBsAg. The a-determinant an
indicated. Bottom: The sequence aa 115–173 of HBsAg. The aa sequence of HBs
(Norder et al., 1993). For mutant sequences, the positions and the nature of the a
changed aa within the wild type adw2 sequence was underlined.anti-HBs antibody (see below). Thus, some specific
mutations at the critical positions within the HBsAg
sequences may change the antigenicity of HBsAg.
The reactivity of antibodies to HBsAg in human subjects
to wt- and mtHBsAg was tested (Fig. 2). Though many
human sera had high titers of anti-HBs antibodies, IF
staining of HBsAg expressing cells using these samples
resulted frequently into strong unspecific staining. The
purification of IgG fractions from sera reduced the
unspecific staining. However, only few IgG preparations
gave positive staining of transfected cells, as shown in Fig.
2. The IgG preparations from sera from two different
individuals recognized normally the mtHBsAg with aa
substitutions within the first half of the a-determinant and
stained the mtHBsAg K141Q, C147W, and S154V with
reduced intensity. The mtHBsAg 145R was not recognized.
Thus, the majority of the tested aa substitutions within the
second loop of the HBsAg a-determinant appeared to reduce
the binding of antibodies to HBsAg.
The mutations G145R and F134S within the a-determinant
of HBsAg impaired the ability to induce the anti-HBs
antibody
The aa substitutions like G145R and F134S affect the
antigenicity of HBsAg in different extents. However, it is
unknown whether mtHBsAg with these aa substitutions
retain the ability to induce anti-HBs antibody response. As
demonstrated in our previous studies, genetic immunizations
in the mouse model represent a useful tool to test the ability of
the mtHBsAg to induce HBsAg-specific antibodies (Lu and
Lorentz, 2003). Genetic immunizations of mice with plas-
mids expressing MHBsAg induce antibodies to the HBVd the murine H-2Ld-restricted CTL epitope aa 28–39 (Ld) of HBsAg are
Ag from aa 115–173 of the HBV subtype adw2 was given as the reference
a substitutions introduced into the wtHBsAg sequence were indicated. The
Fig. 2. IF staining of wtHBsAg and mtHBsAg with HBsAg-specific antibodies. Cells were transfected with plasmids expressing wtHBsAg or mtHBsAg, as
indicated in the figures. After 48 h, cells were fixed with 50% methanol and stained with the anti-HBs antibodies. Polyclonal goat anti-HBs IgG to plasma-
derived HBsAg (Biotrend) and an anti-HBs MAb (Dako, clone 3E7) were used for IF staining. Human anti-HBs IgG P4 was purified from serum of an
individual received immunization with recombinant HBsAg. The intensities of the IF staining were judged by comparison with the staining of wtHBsAg. ++:
strong IF staining, as seen for wtHBsAg; +: weak staining; : no specific staining. Three representative IF staining of wtHBsAg and mtHBsAg with MAb 3E7
are shown (magnification 400). The results of IF staining of nine mtHBsAg and wtHBsAg are listed.
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Zheng et al., 2002). Therefore, the coding sequence for the
HBV preS2 region was added to both mutated s sequences to
generate pS2-HBsAg145R and pS2-HBsAg134S using the
previously cloned sequence (Zheng et al., 2002). This
procedure resulted into plasmid expression of MHBsAg with
aa substitutions G145R and Y134S within the S domain.
Since the HBV preS2 region harbors potent B-cell epitopes
like aa 14–32 (Neurath et al., 1984), it serves as an internal
control for the suitability of the plasmids of genetic
immunizations. As expected, these expression vectors
encoded the MHBsAg that could be detected by polyclonal
anti-HBs antibodies (data not shown).
Four groups of five mice each were immunized twice
with plasmids pHBsAg-WT, pHBsAg145R, pS2-
HBsAg145R, and pS2-HBsAg134S, respectively, in a time
interval of 3 weeks. The immunization with pHBsAg-WT
induced anti-HBs antibodies in four of five mice. Only one
of five mice immunized with pHBsAg145R developed
anti-HBs antibody. Immunizations with pS2-HBsAg145R
and pS2-HBsAg134S did not induce any detectable anti-
HBs antibody (Fig. 3A), though antibodies to MHBsAg
were induced in three and four of five mice, respectively(Fig. 3B). Thus, these aa substitutions within the a-
determinant affected specifically the immunogenicity of
the mtHBsAg.
Though the induction of wtHBsAg-specific antibodies
was impaired, genetic immunizations with plasmids
expressing mtHBsAg induced normal HBsAg-specific
CTL responses in mice. All immunized mice developed
CTLs to HBsAg without an obvious difference between
these different groups. The CTLs to the immunodominant,
H-2Ld-restricted epitope on HBsAg aa 29–38 was analyzed
for each expanded culture (Table 1). Forty-one percent to
75.5% of total cell counts in cultures after 7 days were
positively stained with anti-CD8 MAb. 28.7% to 64.2% of
CD8+ cells were stained with H-2Ld:Ig dimeric protein
loaded with HBsAg aa 29–38. Dimeric proteins loaded with
a control peptide aa 208–215 stained less than 4.5% of
CD8+ cell counts that are supposed to be unspecific
staining. Mice immunized with control plasmids like
pcDNA3 did not develop any HBsAg-specific CTLs (data
not shown). Similar results were obtained by using standard
Cr-release assay (data not shown). These results were
consistent with our previous findings with other mutant
HBsAg (Lu and Lorentz, 2003).
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aa substitution G145R
The a-determinant is the only region with the ability to
induce HBsAg-specific antibodies in genetic immunizations(Schirmbeck et al., 2001; Zheng et al., 2002). Thus, aa
substitutions within the a-determinant may change the
specificity of the antibody responses. Particularly, the
substitution G145R is assumed to affect the conformation
of HBsAg a-determinant. Consequently, such mtHBsAg may
induce antibodies with a changed specificity that do not
efficiently bind to the wtHBsAg. To test the hypothesis, we
attempted to detect the specific antibodies to mtHBsAg in
sera from immunized mice. MtHBsAg was purified from
serum of a patient infected with HBV mutant with an aa
substitution G145R within the a-determinant and coated to
the microtiter plates for ELISA. Sera from mice immunized
with pHBsAg145R or pS2-HBsAg145R showed a significant
reactivity to purified mtHBsAg, whether or not they were
reactive to MHBsAg (Fig. 3C). The reactivity to the
mtHBsAg was clearly measured at dilutions up to 1:200 of
sera. In contrast, sera from pS2-HBsAg134S immunized
mice or control sera did not react at a dilution of 1:25. Thus,
the aa substitution G145R did not abolish the immunoge-
nicity of mtHBsAg but appeared to change the antibody
specificity.
Generation of specific MAb to mtHBsAg
Based on our previous results, it should be possible to
generate antibodies that specifically react to mtHBsAg but
bind to wtHBsAg with a reduced ability. Two groups of
mice were immunized twice with pcDNA3-101 or
pcDNA3-146 (Fig. 4A). The plasmid pcDNA3-146 was
chosen for generation of MAbs because of the availability of
the corresponding recombinant mtHBsAg for boost and
screening of specific MAbs (Weber et al., 2001). Five mice
of the control group received immunizations with pcDNA3-
101 expressing wtHBsAg and developed anti-HBs anti-
bodies (data not shown). Similar to the previous experi-
ments, only one mouse developed anti-HBs antibodies after
two immunizations with pcDNA3-146. This mouse received
an additional boost with 800 ng of recombinant mtHBsAg-
146. Hybridoma cell lines were generated with splenocytes
from this mouse. Supernatants of two hybridoma cell lines
2.001.2 and 2.001.3 showed reactivity to mtHBsAg-146
(Fig. 4B). The MAbs 2.001.2 and 2.00.3 were of subtypes
IgG2b and IgG3, respectively. Interestingly, MAb 2.001.2Fig. 3. Induction of anti-HBs antibodies and HBsAg-specific CTLs in mice
by DNA immunization. BALB/cJ (H-2d) mice were immunized with
plasmids expressing wtHBsAg and mtHBsAg and were sacrificed three
weeks after the last immunization. Sera were collected to test the presence
of antibodies to wtHBsAg and mtHBsAg. (A) Sera from immunized mice
were tested by a commercial kit Enzygnost anti-HBs II (Dade Behring). The
anti-HBs titers were given for each individual mouse. (B) Sera from mice
immunized with pS2-HBsAg145R and pS2-HBsAg134S were tested in
ELISA for their reactivity to MHBsAg. Recombinant MHBsAg was used to
coat the ELISA plates. The anti-HBs titers were given for each individual
mouse. (C) Detection of specific antibodies to the mtHBsAg with G145R.
Plasma-derived HBsAg from a patient carrying mtHBsAg G145R was used
to coat the ELISA plates. Two representative samples from each group were
tested due to the shortage of the mtHBsAg G145R.
Table 1
Induction of CD8+ cells directed to the immunodominant CTL epitope aa
28–39 of HBsAg by plasmid immunization of BALB/cJ (H-2d) mice
Plasmids CD8+ cells/total
cell counts (%)
CD8+ cells
stained with
specific dimer (%)a
CD8+ cells
stained with
control dimer (%)b
wtHBsAg adw
1 41.4 34.1 0.5
2 61.0 28.7 2.9
mtHBsAg G145R
1 58.1 50.7 3.3
2 70.7 55.9 4.2
3 75.5 64.2 4.2
BALB/cJ (H-2d) mice ware immunized with plasmids expressing wtHBsAg
and mtHBsAg G145R and were sacrificed 3 weeks after the last
immunization. Splenocytes from mice were prepared and expanded for 7
days in the presence of P815 cells expressing wtHBsAg. Staining of
expanded splenocytes was performed with antibodies or H-2Ld:Ig dimeric
protein, as indicated. The splenocytes were derived from two and three
mice immunized with wtHBsAg or with mtHBsAg G145R, respectively.
The staining of splenocytes was analyzed by flow cytometry.
a The specific H-2Ld:Ig dimeric protein was prepared by using the peptide
aa 29–38 derived from HBsAg. The percentages were calculated with
CD8+ cell numbers as the baseline.
b The control H-2Ld:Ig dimeric protein was prepared by using the peptide
aa 208–215 derived from HBsAg. The percentages were calculated with
CD8+ cell numbers as the baseline.
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reactive to the wtHBsAg. This result provided evidence that
the mtHBsAg145R was indeed able to induce mutant-
specific antibody.
To test whether MAb 2.001.2 is able to recognize other
mtHBsAg, 2.001.2 was purified from the hybridoma cell
supernatant and used for IF staining. HepG2 cells were
transfected with pS2-HBsAg145R and pS2-HBsAg134S. IF
staining was performed with three MAbs, a high-affinity
anti-HBsAg antibody MAb-No2 (Lu and Lorentz, 2003), the
anti-HBsAg antibody 3E7, and 2.001.2. Both mtHBsAg
were recognized by the high-affine anti-HBs antibody (Figs.
5A,D). The anti-HBs antibody clone 3E7 showed no
staining for S2-HBsAg145R but weak staining for S2-
HBsAg134S, as tested previously (Figs. 5B,E). 2.001.2
recognized S2-HBsAg145R but did not stain S2-
HBsAg134S (Figs. 5C,F). IF staining of other six different
mtHBsAg with 2.001.2 was also negative (data not shown).
These results clearly demonstrated that this MAb to
HBsAg145R was highly specific and did not recognize
other mtHBsAg.Fig. 4. Generation of specific monoclonal antibodies tomtHBsAgwith the aa
substitution G145R. (A) Expression vectors. Two expression vectors for
wtHBsAg and mtHBsAg were generated on the basis the vector E2-TM8
(Tacke et al., 1997) and were used for genetic vaccination of BALB/cJ (H-2d)
mice. (B) Selection of monoclonal antibodies by ELISA. Recombinant
wtHBsAg and mtHBsAg were used test the reactivity of monoclonal
antibodies (Weber et al., 2001). The culture supernatants of hybridomas were
tested for the reactivity of monoclonal antibodies. White bar: antibody to
wtHBsAg; black bar: antibody to mtHBsAg HB-146.Discussion
Though many aa substitutions within the HBsAg a-
determinant are identified in HBV isolates, the majority of
single aa substitutions appear to have a limited influence on
the antigenicity of HBsAg. In addition, the imunogenicity of
HBsAg is not necessary to be impaired if aa substitutionsoccur within the HBsAg a-determinant and reduce the
binding of anti-HBs antibodies. Many mtHBsAg were able
to induce normal anti-HBs antibodies by genetic immuniza-
tion (our unpublished results). The mtHBsAg G145R is of
particularly interesting since this aa substitution occurs often
in patients and has a strong influence on the HBsAg
antigenicity. In this paper, we clearly demonstrated that the
mtHBsAg G145R was immunogenic and was able to induce
mutant-specific antibody response in mice. The HBsAg a-
determinant is the only immunogenic region on the small
wtHBsAg polypeptide and possesses complex conforma-
tional epitopes. Therefore, aa substitutions within the a-
determinant lead to conformational changes and affect the
antigenicity and immunogenicity in different extent. Some
aa substitutions like G145R result presumably into a
significant conformational change of the HBsAg a-determi-
nant. This conformational change does not simply lead to
the loss of immunogenicity, but creates a new specificity.
The mtHBsAg G145R retained partly the ability to induce
antibodies to wtHBsAg. Few mice immunized with plas-
mids expression mtHBsAg G145R developed detectable
anti-HBs antibody titers. In addition, one MAb 2.001.3
showed a cross-reactivity to wtHBsAg and mtHBsAg
G145R. Consistently, infection of chimpanzees with a
HBV mutant isolate carrying the mutation G145R induced
anti-HBs antibody response (Ogata et al., 1997). MAb
Fig. 5. IF staining of wtHBsAg and mtHBsAg with MAbs. HepG2 cells were transfected with plasmids expressing wtHBsAg or mtHBsAg, as indicated in the
figures. After 48 h, cells were fixed with 50% methanol and stained with the anti-HBs MAbs. (A–C) pHBsAg145R; (D–F) pHBsAg134S. For IF staining, three
different mouse MAbs were used: A and D with a high-affinity anti-HBs MAb-No2, B and E with anti-HBs clone 3E7, and C and F with MAb 2000.2.
Magnification, 400.
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G145R but not that with F134S and others. Thus, the MAb
2.001.2 is directed to the epitope involving the aa
substitution G145R.
In our study, the majority of mtHBsAg with single aa
substitutions was recognized by anti-HBs antibodies. Thus,
aa substitutions do not generally abolish the binding of anti-
HBs antibodies to the mtHBsAg. Only few aa substitutions
strongly affected the recognition of mtHBsAg by anti-HBs
antibodies. A large number of natural HBV isolates with aa
substitutions within the HBsAg a-determinant were
described. Multiple aa substitutions may occur often in
one isolate and may contribute collectively to the reduction
of antibody binding. In our previous study, we found two
coexisting HBsAg mutants K29 and K30 that differ in one
aa residue at the position 144. The binding of certain anti-
HBs MAbs to mtHBsAg appeared to be influenced by the aa
substitution at position 144, though this aa substitution itself
did not obviously affect the overall antigenicity of HBsAg
(Lu and Lorentz, 2003).
The infection with mutant HBV in human is still not
investigated in details. HBV mutants may infect unvacci-
nated persons (Oon et al., 2000). Since HBV vaccines
induce T- and B-cell responses, HBV may be not able to
infect immunized persons only by escaping from antibody
responses, as shown by the experimental infection in
chimpanzees (Ogata et al., 1999). Mutant HBV may get a
chance to cause acute and chronic infection in individuals
with impaired cellular immune response, for example, by
immune suppression or AIDS. It is not yet investigated howmutant HBV infect young vaccinees, as described in
different studies (Hino et al., 2001; Karthigesu et al.,
1994). Newborns may have a not fully functional T-cell
response and are susceptible to infections with mutant HBV
despite combined active and passive vaccinations against
HBV.
In addition, the impact of the natural variation of HBVon
T-cell responses in humans is not investigated. The natural
HBV isolates has a great genetic variability through the
whole genome (reviewed by Gunther et al., 1999). Accor-
ding to the sequence information, HBV isolates are divided
into six major subtypes. The sequence diversity between
subtypes is found to be greater than 15%. Since the
currently available vaccines will only induce an immune
response targeting a limited spectrum of T- and B-cell
epitopes, HBV isolates of different genotypes will not be
controlled with the equal efficiency. Recently, Schirmbeck
et al. (2003) have shown in the mouse model that naturally
occurring, single, conservative aa substitutions in the
HBsAg subtypes can change CD8+ T-cell repertoire to viral
antigens. Further studies will be necessary to clarify the
implications of the genetic diversity of HBV for T-cell
responses.
The anti-HBs MAbs bind to wtHBsAg and mtHBsAg
differently. The observed binding of an anti-HBs antibody is
a sum of the affinity of the MAb to HBsAg, the
concentration of the MAb used in IF staining, the position
and the nature of aa substitutions, and many other factors
like the experiment procedure. Thus, it is still difficult to
compare the data published about the numerous aa
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of antibodies to describe mtHBsAg.Materials and methods
Construction of plasmids encoding HBsAg with single
mutations within the a-determinant by site-directed
mutagenesis
A cloned HBV genome of the subtype adw2 pHBV991-
12-1 (GenBank accession number X51970) was used as the
backbone of the mutated HBV s gene. The cloned DNAwas
extracted from E. coli and subjected to PCR amplification.
The region encoding the HBsAg (nt 11–1027 according the
numbering of pHBV991-12-1) of HBV was amplified using
KS13 (nt 11–36, 5V-CCT TCC ACC AAA CTC TGC AAG
ATC CC-3V) and KS14 (nt 1027–1005, 5V-GGA GCA GCA
AAG CCC AAA AGA CC-3V) and cloned into pCR2.1
vector (Weinberger et al., 2000). The correctness of the
sequence was verified by DNA sequencing analysis of the
cloned fragments. Mutations were introduced by PCR-based,
site-directed mutagenesis using specific primers. TheWTand
mutated HBV s genes were recloned into the EcoRI site of the
expression vector pcDNA3 and tested for the expression of
HBsAg by transient transfection in hepG2 cells.
The coding sequence for the HBV preS2 region was
added to both mutated s sequences to generate pS2-
HBsAg145R and pS2-HBsAg134S using the previously
cloned sequence (Zheng et al., 2002). This procedure
resulted into plasmids expressing MHBsAg with aa
substitutions G145R and Y134S within the S domain.
Two additional expression vectors for immunizations
were constructed on the basis of the expression vector E2-
TM8, a modified version of pcDNA3 with an EPO leader
sequence and a FLAG-tag (Tacke et al., 1997). Two
previously characterized clones with known sequences
encoding a WT and a mutated HBV s gene of the subtype
adw were selected (Seddigh-Tonekaboni et al., 2000). The
HBV sequences were reamplified with the primers FS NotI
5V-GAG GCG GCC GCC ATG GAG AAC ATC ACATCA
(nt 154–172) GG-3Vand RS ApaI 5V-CAG GGG CCC CTA
TTA AAT GTA TAC CCA GAG AC-3V (nt 832–816),
restricted with NotI and ApaI, and inserted into E2-TM8
predigested with NotI and ApaI. The correctness of the
cloned sequences was verified by sequence analysis. These
procedures resulted into two expression vectors pcDNA3-
101 and pcDNA3-146 expressing wtHBsAg and mtHBsAg
with triple aa substitutions P142S/G145R/N146D (See
below, Fig. 4A). These plasmids were used for genetic
immunizations to generate MAbs in mice.
Transient transfection with the expression plasmids
HepG2 cells or baby hamster kidney cells (105 per well)
were maintained in appropriate media, supplemented with10% fetal calve serum (FCS) in a eight-well tissue culture
chamber slides at 37 8C and 5% CO2 until the cells reached
approximately 50–80% confluence. One to 2 Ag of DNA
plasmids and 2 Al of LIPOFECTAMINE (GIBCO BRL,
Neu-Isenburg, Germany) were diluted with 18 Al of OPTI-
MEM, respectively, and then mixed. Following 30–45-min
incubation at room temperature, DNA–liposome complexes
were diluted in 160 Al of OPTI-MEM and slowly added to
prewashed cells. 0.4 ml of fresh RPMI 1640 or MEM
containing 10% FCS was added to cells and incubation was
continued for 48 h. Supernatants from each well were
collected and stored at 20 8C for detection of HBsAg.
Transfected cells were washed twice with phosphate-
buffered saline (PBS) and fixed with 50% methanol at
4 8C for 30 min for IF staining.
IF staining of transfected cells
Polyclonal goat anti-HBs antibodies to plasma-derived
HBsAg of ad and ay types (Biotrend, Kfln, Germany. 1:80
dilution with PBS), and monoclonal mouse anti-HBsAg daT
antibodies (Dako, Hamburg, Germany, or Roche, Penzberg,
Germany, 1:100 dilution with PBS) were used as primary
antibodies for IF staining. One hundred microliters of
diluted antibodies were added into each well. After
incubation 1 h at 37 8C, cells were washed with PBS three
times. Anti-goat-IgG FITC (1:80 dilution) or anti-mouse-
IgG FITC (1:100 dilution) were used as secondary anti-
bodies. All of the second antibodies were diluted with PBS
containing 0.1% Evans Blue and were incubated at 37 8C
for 1 h. Thereafter, cells were washed with PBS and covered
with mounting medium for fluorescence microscopy (Zheng
et al., 2002).
In addition, IgG fractions were purified from anti-HBs
positive human sera by ammonium sulfate precipitation or
by protein-G column. Staining of transfected cells were
performed with IgG fraction at a dilution up to 1:10 in PBS.
FITC labeled anti-human IgG antibodies (Dako) were used
as secondary antibody a dilution 1:100.
DNA-based immunization of mice
BALB/cJ (H-2d) mice were kept under standard-patho-
gen-free conditions in the Central Animal Laboratory of
University Essen. Mice of 6–8 weeks of age were immu-
nized intramuscularly (i.m.) with 100 Ag of plasmid DNA as
described previously (Lu and Lorentz, 2003; Schirmbeck et
al., 1995). The mice received two immunizations in a time
interval of 3 weeks and were sacrificed 3 weeks after the last
immunization for determination of serum antibody titers to
HBsAg, MHBsAg, and mtHBsAg with the aa substitution
G145R, and for the detection of HBsAg-specific cytotoxic
T-lymphocytes (CTL).
The antibodies to HBsAg in serum samples were
detected by the standard commercial assay Enzygnost
anti-HBs II kit (Behring, Marburg, Germany) according to
X. Zheng et al. / Virology 329 (2004) 454–464462the manufacturer’s instructions. The detection of specific
antibodies to MHBsAg was performed as described in
following protocol: plates were coated with 10 Ag of
recombinant HBsAg containing large and middle HBsAg
per ml in 0.1 M carbonate buffer [pH 9.6] at 37 8C for 1 h
and then blocked with 100 Al of 5% FCS for 1 h at 37 8C
(the antigens were provided by Dr. J. Reimann; Diminsky et
al., 1997). Fifty microliters of mouse serum samples at
dilutions 1:10–1:1000 were dispensed into the wells and
incubated at 37 8C for 1 h. After washing, 50 Al of
horseradish peroxidase-conjugated rabbit anti-mouse-IgG at
a dilution 1:1000 was added into each well for 1 h at 37 8C.
Fifty microliters of dissolved O-phenylenediamine (Sigma-
Aldrich Co., Steinheim, Germany) was added as the
substrate of horseradish peroxidase into the wells. The
development of color occurred at room temperature and was
read at 490 nm. The cutoff value was set as three times over
negative controls. For detection and titration of antibodies to
HBsAg with the aa substitution G145R, mtHBsAg was
purified from plasma of a patient and used for ELISA.
For detection of HBsAg-specific CTLs, spleens were
taken from sacrificed mice. Splenocytes were cultured with
P815 cells expressing HBsAg (kindly provided by Dr. F. V.
Chisari) for 5 days. The portion of specific CTLs directed to
the dominant H-2Ld-restricted epitope on HBsAg aa 29–38
was determined by the dimer technology (BD Biosciences,
CA) according to the manufacturerVs instructions. Recombi-
nant soluble dimeric H-2Ld:IgG molecules were loaded by
incubation with 460 molar excess of the HBsAg-derived
peptides aa 29–38 or aa 208–215 at 4 8C for 48 h. The
peptide aa 208–215 is a H-2Kb-restricted CTL epitope and
serves as control. The peptides were purchased from EMC
microcollections GmbH (Tqbingen, Germany) and had a
purity N80%. Cultured mouse splenocytes were washed
with BD PharMingen staining buffer (BD Biosciences) and
concentrated to 5  106 per milliliter. Two microliters of
peptide-loaded H-2Ld:IgG were added to 200 Al of cultured
splenocytes and incubated at 4 8C for 1 h. After three
washes, splenocytes were incubated with 2 Al of anti-CD8a
FITC (clone 53–6.7) and 2 Al of PE-labeled anti-mouse
IgG1. All antibodies used in these experiments were
purchased from BD Biosciences. After staining with labeled
antibodies, cells were washed twice, resuspended in 0.5 ml
of staining buffer in a tube, and subjected to flow cytometry.
Due to the previous in vitro expansion, the above-described
method allows only the qualitative detection of specific
CTLs. In addition, HBsAg-specific CTLs were detected by
Cr-release assay using 51Cr-labeled P815 target cells as
described previously (Lu and Lorentz, 2003).
Generation of specific MAbs to mtHBsAg with the mutation
G145R
Two expression vectors pcDNA3-101 and pcDNA3-146
were constructed for the genetic immunization of mice. The
plasmid pcDNA3-101 expressing the WT adw HBsAg wasused as a positive control for the immunization procedure.
BALB/cJ (H-2d) mice were immunized twice with plasmids.
One mouse immunized with pcDNA3-146 was further
boosted with 800 ng of recombinant mtHBsAg with
respective mutations (Weber et al., 2001). Five days after
the boost with the recombinant mtHBsAg, hybridoma cells
were generated with splenocytes from this mouse and tested
for the reactivity to wtHBsAg and mtHBsAg. The selection
of the hybridoma cell lines was performed by testing the
reactivity of hybridoma supernatants to wtHBsAg and
mtHBsAg in ELISA. Two hybridoma cell lines 2.001.2
and 2001.3 were generated to produce MAbs to mtHBsAg
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